Another biotech day, another biotech microcap disaster.
Today’s turn goes to Tenax Therapeutics $TENX, a Morrisville, NC company which reported this morning that its Phase III study of its lead drug levosimendan “did not achieve statistically significant reductions in the dual endpoint of death or use of a mechanical assist device at 30 days, nor in the quad endpoint of death, myocardial infarction, need for dialysis, or use of a mechanical assist device at 30 days.”
Tenax, with a market cap that started this morning at $54 million, still asserts that it may be able to blaze a path forward, focusing on two positive secondary endpoints for a “reduction in low cardiac output syndrome (LCOS) and a reduction in postoperative use of secondary inotropes.”
That would be a rare event, though. And investors weren’t going for the ride. The company’s stock was eviscerated, dropping 75% into penny stock territory.
This isn’t the first brush with disaster for Tenax. Formerly known as Oxygen Bio, the company had to endure a clinical hold on a drug aimed at speeding recovery for brain injuries, only to scrap the effort a little more than two years ago citing enrollment woes.
As Tenax, the company moved on to levosimendan, which it in-licensed for $5 million in company stock. The drug is marketed in 50 countries, outside the US.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.Free Subscription